Skip to main content
Kwality Pharmaceuticals Limited logo

Kwality Pharmaceuticals Limited — Investor Relations & Filings

Ticker · KPL ISIN · INE552U01010 LEI · 894500ESL4TD9PBB7Y28 BSE.NS Manufacturing
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-05-22 Report Publication Anno…
Country IN India
Listing BSE.NS KPL

About Kwality Pharmaceuticals Limited

https://www.kwalitypharma.com/

Kwality Pharmaceuticals Limited specializes in the development, manufacture, and export of a comprehensive range of pharmaceutical formulations. The company operates advanced manufacturing facilities designed to produce diverse dosage forms, including tablets, capsules, liquid orals, dry syrups, and sterile injections, encompassing both liquid and dry powder vials. Its product portfolio spans multiple therapeutic categories, such as oncology, ophthalmology, cardiovascular, and anti-infectives. The organization is characterized by its adherence to international quality standards and WHO-GMP certifications. Beyond its own product lines, the company provides extensive contract manufacturing and formulation development services to global partners. By leveraging modern technology and rigorous quality control processes, it serves a broad international client base across various regulated and semi-regulated markets.

Recent filings

Filing Released Lang Actions
Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026.
Report Publication Announcement Classification · 89% confidence The document is a letter from Kwality Pharmaceuticals to BSE notifying the exchange that the company’s audited financial results for the quarter and year ended March 31, 2026 have been published in newspapers (Financial Express and Punjabi Jagran) and attaching a copy of that publication. It does not contain full financial statements or substantive analysis itself, but is an announcement of report publication. Hence it should be classified as a Report Publication Announcement.
2026-05-22 English
Transcript of Earning Conference Call of Q4FY2026.
Call Transcript Classification · 98% confidence The document is headed “Transcript of Earnings Conference Call – Q4FY26” and contains a verbatim transcript of the analyst/earnings call, including a moderator, management presentation, and investor Q&A. This matches the definition of a Call Transcript (CT).
2026-05-21 English
Investor Presentation for the quarter and year ended 31st March, 2026.
Investor Presentation Classification · 95% confidence The document is clearly a slide-based presentation titled “Q4 & FY26 Investor Presentation” containing forward‐looking statements, financial highlights, business updates, growth strategy, manufacturing capabilities, R&D pipeline, and capex plans. It is not regulatory certification or a full statutory report but a narrative investor slide deck, matching the definition of an Investor Presentation (IP).
2026-05-19 English
Audited Financial Results for the quarter and year ended 31st March, 2026.
Interim / Quarterly Report Classification · 85% confidence The document is an official outcome of a Board Meeting under SEBI LODR regulations, announcing and enclosing the Audited Standalone and Consolidated Financial Results for the quarter and full year ended March 31, 2026. It includes the full financial statements (P&L, A&L, Cash Flow) rather than just a brief highlights release, and it is not the full annual report but a periodic financial report for the quarter. This matches our definition of an Interim / Quarterly Report (Code: IR). FY 2026
2026-05-19 English
Audited Financial Results for the quarter and year ended 31st March, 2026
Earnings Release Classification · 83% confidence The document is a stock-exchange filing under SEBI LODR Regulations 30 & 33 announcing and enclosing the Audited Standalone and Consolidated Financial Results for Q4 and the full year ended March 31, 2026. It includes a management narrative of key highlights and then the actual financial statements (assets & liabilities, P&L, cash flows). This is not a full annual report (10-K) but an earnings announcement of periodic results submitted to the stock exchange. Therefore it is classified as an Earnings Release (ER). FY 2026
2026-05-19 English
Intimation of Analysts/Investors Conference Call to be held on May 19, 2026 at 5:00 P.M. to discuss Q4 FY26 financial results.
Regulatory Filings Classification · 80% confidence The document is a short exchange filing pursuant to SEBI Listing Regulation 30, informing the stock exchange of a scheduled analysts/investors conference call to discuss Q4 FY26 financial results. It does not contain financial results, transcripts, slides, or an actual report; it is simply a regulatory announcement of an event. This fits the fallback category Regulatory Filings (RNS) for general compliance disclosures and event notices.
2026-05-14 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.